Shuttle Pharma completes enrollment agreements for Phase 2 Ropidoxuridine glioblastoma trial

Shuttle Pharmaceuticals Holdings, Inc.

All six trial sites finalized: Georgetown, UNC, UVA, Hackensack, Allegheny Health Network, Miami Cancer Institute.
Patient screening underway; 40 patients randomized to 1,200 mg/day or 960 mg/day dose groups.
Optimal dose group will add 14 patients for survival comparison vs historical controls; trial completion in 18-24 months.
Ropidoxuridine holds FDA Orphan Drug Designation for glioblastoma, offering potential marketing exclusivity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.